tetano
Editor, Senior Moderator
Clin Kidney J
. 2021 Dec 27;15(3):527-533.
doi: 10.1093/ckj/sfab291. eCollection 2022 Mar.
Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant
Mariana Seija[SUP] 1 [/SUP], Florencia Rammauro[SUP] 2 [/SUP], José Santiago[SUP] 1 [/SUP], Natalia Orihuela[SUP] 3 [/SUP], Catherine Zulberti[SUP] 3 [/SUP], Danilo Machado[SUP] 4 [/SUP], Cecilia Recalde[SUP] 4 [/SUP], Javier Noboa[SUP] 1 [/SUP], Victoria Frantchez[SUP] 5 [/SUP], Rossana Astesiano[SUP] 1 [/SUP], Federico Yandián[SUP] 1 [/SUP], Ana Guerisoli[SUP] 1 [/SUP], Álvaro Morra[SUP] 3 [/SUP], Daniela Cassinelli[SUP] 6 [/SUP], Cecilia Coelho[SUP] 6 [/SUP], Belén de Aramburu[SUP] 6 [/SUP], Paulina González-Severgnini[SUP] 6 [/SUP], Romina Moreno[SUP] 6 [/SUP], Aldana Pippolo[SUP] 6 [/SUP], Gabriela López[SUP] 7 [/SUP], Mónica Lemos[SUP] 7 [/SUP], Lorena Somariva[SUP] 7 [/SUP], Eliana López[SUP] 7 [/SUP], Soledad Fumero[SUP] 7 [/SUP], Carla Orihuela[SUP] 7 [/SUP], Rosalía Rodríguez[SUP] 4 [/SUP], Gonzalo Acuña[SUP] 4 [/SUP], Victoria Rabaza[SUP] 4 [/SUP], Nancy Perg[SUP] 4 [/SUP], Rossana Cordero[SUP] 4 [/SUP], Cristina Reisfeld[SUP] 4 [/SUP], Paula Olivera[SUP] 4 [/SUP], Paola Montero[SUP] 4 [/SUP], Cecilia Nogueira[SUP] 4 [/SUP], Catheryn Nalerio[SUP] 3 [/SUP], Sergio Orihuela[SUP] 3 [/SUP], Lilián Curi[SUP] 3 [/SUP], Ema Burgstaller[SUP] 4 [/SUP], Oscar Noboa[SUP] 1 [/SUP], Otto Pritsch[SUP] 2 [/SUP], Marcelo Nin[SUP] 1 [/SUP], Sergio Bianchi[SUP] 8 [/SUP]
Affiliations
Abstract
Background: Antibody response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after mRNA or adenoviral vector-based vaccines is weak in kidney transplant (KT) patients. However, few studies have focused on humoral response after inactivated virus-based vaccines in KT. Here, we compare antibody response following vaccination with inactivated virus (CoronaVac®) and BNT162b2 mRNA.
Methods: A national multicentre cross-sectional study was conducted. The study group was composed of patients from all KT centres in Uruguay, vaccinated between 1 and 31 May 2021 (CoronaVac®, n = 245 and BNT162b2, n = 39). The control group was constituted of 82 healthy individuals. Participants had no prior confirmed coronavirus disease 2019 (COVID-19) test. Blood samples were collected between 30 and 40 days after the second dose. Serum-specific immunoglobulin G (IgG) antibodies against the receptor-binding domain (RBD) of SARS-CoV-2 Spike protein were determined using the COVID-19 IgG QUANT ELISA Kit.
Results: Only 29% of KT recipients showed seroconversion (36.5% BNT162b2, 27.8% inactivated virus, P = 0.248) in comparison with 100% in healthy control with either vaccine. Antibody levels against RBD were higher with BNT162b mRNA than with inactivated virus [median (interquartile range) 173 (73-554) and 29 (11-70) binding antibody units (BAU)/mL, P < 0.034] in KT and 10 times lower than healthy control [inactivated virus: 308 (209-335) and BNT162b2: 2638 (2608-3808) BAU/mL, P < 0.034]. In multivariate analysis, variables associated with negative humoral response were age, triple immunosuppression, estimated glomerular filtration rate and time post-KT.
Conclusion: Seroconversion was low in KT patients after vaccination with both platforms. Antibody levels against SARS-CoV-2 were lower with inactivated virus than BNT162b mRNA. These findings support the need for strategies to improve immunogenicity in KT recipients after two doses of either vaccine.
Keywords: COVID-19; SARS-CoV-2 vaccine; kidney transplantation.
. 2021 Dec 27;15(3):527-533.
doi: 10.1093/ckj/sfab291. eCollection 2022 Mar.
Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant
Mariana Seija[SUP] 1 [/SUP], Florencia Rammauro[SUP] 2 [/SUP], José Santiago[SUP] 1 [/SUP], Natalia Orihuela[SUP] 3 [/SUP], Catherine Zulberti[SUP] 3 [/SUP], Danilo Machado[SUP] 4 [/SUP], Cecilia Recalde[SUP] 4 [/SUP], Javier Noboa[SUP] 1 [/SUP], Victoria Frantchez[SUP] 5 [/SUP], Rossana Astesiano[SUP] 1 [/SUP], Federico Yandián[SUP] 1 [/SUP], Ana Guerisoli[SUP] 1 [/SUP], Álvaro Morra[SUP] 3 [/SUP], Daniela Cassinelli[SUP] 6 [/SUP], Cecilia Coelho[SUP] 6 [/SUP], Belén de Aramburu[SUP] 6 [/SUP], Paulina González-Severgnini[SUP] 6 [/SUP], Romina Moreno[SUP] 6 [/SUP], Aldana Pippolo[SUP] 6 [/SUP], Gabriela López[SUP] 7 [/SUP], Mónica Lemos[SUP] 7 [/SUP], Lorena Somariva[SUP] 7 [/SUP], Eliana López[SUP] 7 [/SUP], Soledad Fumero[SUP] 7 [/SUP], Carla Orihuela[SUP] 7 [/SUP], Rosalía Rodríguez[SUP] 4 [/SUP], Gonzalo Acuña[SUP] 4 [/SUP], Victoria Rabaza[SUP] 4 [/SUP], Nancy Perg[SUP] 4 [/SUP], Rossana Cordero[SUP] 4 [/SUP], Cristina Reisfeld[SUP] 4 [/SUP], Paula Olivera[SUP] 4 [/SUP], Paola Montero[SUP] 4 [/SUP], Cecilia Nogueira[SUP] 4 [/SUP], Catheryn Nalerio[SUP] 3 [/SUP], Sergio Orihuela[SUP] 3 [/SUP], Lilián Curi[SUP] 3 [/SUP], Ema Burgstaller[SUP] 4 [/SUP], Oscar Noboa[SUP] 1 [/SUP], Otto Pritsch[SUP] 2 [/SUP], Marcelo Nin[SUP] 1 [/SUP], Sergio Bianchi[SUP] 8 [/SUP]
Affiliations
- PMID: 35198159
- PMCID: PMC8755301
- DOI: 10.1093/ckj/sfab291
Abstract
Background: Antibody response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after mRNA or adenoviral vector-based vaccines is weak in kidney transplant (KT) patients. However, few studies have focused on humoral response after inactivated virus-based vaccines in KT. Here, we compare antibody response following vaccination with inactivated virus (CoronaVac®) and BNT162b2 mRNA.
Methods: A national multicentre cross-sectional study was conducted. The study group was composed of patients from all KT centres in Uruguay, vaccinated between 1 and 31 May 2021 (CoronaVac®, n = 245 and BNT162b2, n = 39). The control group was constituted of 82 healthy individuals. Participants had no prior confirmed coronavirus disease 2019 (COVID-19) test. Blood samples were collected between 30 and 40 days after the second dose. Serum-specific immunoglobulin G (IgG) antibodies against the receptor-binding domain (RBD) of SARS-CoV-2 Spike protein were determined using the COVID-19 IgG QUANT ELISA Kit.
Results: Only 29% of KT recipients showed seroconversion (36.5% BNT162b2, 27.8% inactivated virus, P = 0.248) in comparison with 100% in healthy control with either vaccine. Antibody levels against RBD were higher with BNT162b mRNA than with inactivated virus [median (interquartile range) 173 (73-554) and 29 (11-70) binding antibody units (BAU)/mL, P < 0.034] in KT and 10 times lower than healthy control [inactivated virus: 308 (209-335) and BNT162b2: 2638 (2608-3808) BAU/mL, P < 0.034]. In multivariate analysis, variables associated with negative humoral response were age, triple immunosuppression, estimated glomerular filtration rate and time post-KT.
Conclusion: Seroconversion was low in KT patients after vaccination with both platforms. Antibody levels against SARS-CoV-2 were lower with inactivated virus than BNT162b mRNA. These findings support the need for strategies to improve immunogenicity in KT recipients after two doses of either vaccine.
Keywords: COVID-19; SARS-CoV-2 vaccine; kidney transplantation.